Ken Griffin Abeona Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 39,500 shares of ABEO stock, worth $173,800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,500
Previous 10,600
272.64%
Holding current value
$173,800
Previous $53,000
439.62%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ABEO
# of Institutions
65Shares Held
14.4MCall Options Held
715KPut Options Held
58K-
Adage Capital Partners Gp, L.L.C. Boston, MA3.25MShares$14.3 Million0.05% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.31MShares$10.2 Million1.08% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.99MShares$8.74 Million0.01% of portfolio
-
Western Standard LLC Los Angeles, CA1.36MShares$5.99 Million4.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.1MShares$4.85 Million0.0% of portfolio
About ABEONA THERAPEUTICS INC.
- Ticker ABEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,950,380
- Market Cap $26.2M
- Description
- Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...